Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05075889 · ClinicalTrials.gov registry record · Early Phase 1
Utility of ICG in Benign Bone Tumors
A Early Phase 1 study of Bone Tumor, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT05075889 is a Early Phase 1 study of Bone Tumor that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05075889, a Early Phase 1 study of Bone Tumor, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluorescence images will be obtained using a non-invasive fluorescence camera.
Conditions Studied
Interventions
- DRUG Indocyanine Green
Study Locations (1)
New Hampshire
- Dartmouth-Hitchock - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-11-11 |
| Est. Completion | 2022-04-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05075889
The ClinicalTrials.gov registry entry for NCT05075889 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bone Tumor appearing as the primary indexed condition, and to 1 intervention - of which Indocyanine Green is the first listed.
NCT05075889 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05075889 about?
NCT05075889 is a clinical study titled "Utility of ICG in Benign Bone Tumors". Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluore...
What is the current status of trial NCT05075889?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2021-11-11. Estimated completion is 2022-04-20.
What conditions does trial NCT05075889 study?
This clinical trial studies the following conditions: Bone Tumor.
What interventions are being tested in trial NCT05075889?
The interventions under investigation include: Indocyanine Green (DRUG).
Who is sponsoring clinical trial NCT05075889?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05075889 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.